Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther Peters

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
International Journal of Pharmaceutics|February 14, 2016
Response to letter to editorEsther Peters, Jasper Stevens, Peter Pickkers
Nephron. Clinical Practice|October 25, 2014
The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injuryEsther Peters, Rosalinde Masereeuw, Peter Pickkers
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 28, 2014
Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patientsEsther Peters, Suzanne Heemskerk, Rosalinde Masereeuw, et al.
Critical Care (London, England)|August 5, 2018
A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations auditEsther Peters, Massimo Antonelli, Xavier Wittebole, et al.
Shock (Augusta, Ga.)|January 12, 2018
Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and SepsisChristopher Geven, Esther Peters, Mathias Schroedter, et al.
Toxicology and Applied Pharmacology|November 6, 2016
Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injuryEsther Peters, Bülent Ergin, Asli Kandil, et al.
Thrombosis and Haemostasis|September 23, 2016
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humansRahajeng N Tunjungputri, Esther Peters, André van der Ven, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 8, 2012
Alkaline phosphatase as a treatment of sepsis-associated acute kidney injuryEsther Peters, Andrea van Elsas, Suzanne Heemskerk, et al.
BMJ Open|September 29, 2016
Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)Esther Peters, Ravindra L Mehta, Patrick T Murray, et al.
International Journal of Pharmaceutics|September 2, 2015
Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphataseEsther Peters, Jasper Stevens, Jacques Arend, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
International Journal of Pharmaceutics|February 14, 2016
Response to letter to editorEsther Peters, Jasper Stevens, Peter Pickkers
Nephron. Clinical Practice|October 25, 2014
The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injuryEsther Peters, Rosalinde Masereeuw, Peter Pickkers
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 28, 2014
Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patientsEsther Peters, Suzanne Heemskerk, Rosalinde Masereeuw, et al.
Critical Care (London, England)|August 5, 2018
A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations auditEsther Peters, Massimo Antonelli, Xavier Wittebole, et al.
Shock (Augusta, Ga.)|January 12, 2018
Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and SepsisChristopher Geven, Esther Peters, Mathias Schroedter, et al.
Toxicology and Applied Pharmacology|November 6, 2016
Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injuryEsther Peters, Bülent Ergin, Asli Kandil, et al.
Thrombosis and Haemostasis|September 23, 2016
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humansRahajeng N Tunjungputri, Esther Peters, André van der Ven, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 8, 2012
Alkaline phosphatase as a treatment of sepsis-associated acute kidney injuryEsther Peters, Andrea van Elsas, Suzanne Heemskerk, et al.
BMJ Open|September 29, 2016
Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)Esther Peters, Ravindra L Mehta, Patrick T Murray, et al.
International Journal of Pharmaceutics|September 2, 2015
Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphataseEsther Peters, Jasper Stevens, Jacques Arend, et al.
Pageof 2